Company Description
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States.
The company’s lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles.
It has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD; Vectura; The University of North Carolina at Chapel Hill; GlaxoSmithKline; Alcon Inc; and promotion Agreement with Sandoz.
Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
| Country | United States |
| Founded | 2004 |
| IPO Date | Jul 26, 2018 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 216 |
| CEO | Roger Jeffs |
Contact Details
Address: 419 Davis Drive, Suite 100 Morrisville, North Carolina 27560 United States | |
| Phone | 919 328 4400 |
| Website | liquidia.com |
Stock Details
| Ticker Symbol | LQDA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001330436 |
| CUSIP Number | 53635D202 |
| ISIN Number | US53635D2027 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dr. Roger A. Jeffs Ph.D. | Chief Executive Officer and Director |
| Michael Kaseta | Chief Operating Officer and Chief Financial Officer |
| Russell Schundler | General Counsel and Corporate Secretary |
| Dana Boyle | Chief Accounting Officer |
| Christian Perez Font | Senior Vice President, Chief Compliance Officer and Associate General Counsel |
| Michael Post | Senior Vice President of Marketing |
| Matt Snow | Senior Vice President of Sales |
| Sarah Krepp SPHR | Chief Human Resources Officer |
| Jason Adair | Chief Business Officer |
| Scott Moomaw | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 16, 2021 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 30, 2020 | 15-12B | Securities registration termination |
| Nov 20, 2020 | EFFECT | Notice of Effectiveness |
| Nov 20, 2020 | EFFECT | Notice of Effectiveness |
| Nov 20, 2020 | 144 | Filing |
| Nov 18, 2020 | 25-NSE | Filing |
| Nov 18, 2020 | POS AM | Post-Effective amendments for registration statement |
| Nov 18, 2020 | POS AM | Post-Effective amendments for registration statement |
| Nov 18, 2020 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Nov 18, 2020 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |